Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.
Inflammatory conditions, such as rheumatoid arthritis, reduce response to calcium channel and beta-adrenergic antagonists but not the angiotensin II type 1 receptor (AT(1)R) antagonist valsartan. Inflammation also reduces clearance of some drugs or active metabolite, thereby reducing response. Active (n = 14) and controlled rheumatoid arthritis (n = 12) and healthy subjects (n = 12) received losartan (100 mg). Blood pressures were measured, and samples were taken for pharmacokinetic and inflammatory mediator concentration determination. Active disease significantly increased arthritic index, nitric oxide, and Creactive protein. Although no between-group difference in plasma losartan concentration-time curves was observed, concentrations of the active metabolite, EXP 3174, were significantly reduced by arthritis. This, however, was not accompanied by reduced clinical response. One subject produced no detectable concentrations of EXP 3174 likely due to insufficient CYP2C9 activity. Despite reduced concentrations of the active metabolite, AT1R antagonists potency does not appear to be reduced by inflammation.
Daneshtalab
Noriko
N
Faculty of Pharmacy, University of Alberta, Edmonton, Alberta, Canada, T6G-2N8.
Lewanczuk
Richard Z
RZ
Russell
Anthony S
AS
Jamali
Fakhreddin
F
D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001172:Arthritis, Rheumatoid / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006207:Half-Life; D006801:Humans; D019808:Losartan / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged
D000959:Antihypertensive Agents; D019808:Losartan